Clinical data show an association of high very prolactin levels with increased prevalence of obesity and metabolic disorders such as dyslipidemia, glucose intolerance, and insulin resistance, and many of these disorders are improved by normalizing prolactin levels with dopamine agonists (8, 11–17). This evidence concerns the gene PRL and Other metabolic disease.